carmustine has been researched along with Duncan Disease in 6 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In an attempt to reduce the high procedure-related mortality reported with allografting in lymphoma, we have used BEAM (BCNU, etoposide, cytarabine and melphalan), a standard conditioning regimen for autologous transplantation." | 3.70 | Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. ( Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gil, L | 1 |
| Kozlowska-Skrzypczak, M | 1 |
| Mol, A | 1 |
| Poplawski, D | 1 |
| Styczynski, J | 1 |
| Komarnicki, M | 1 |
| Lush, RJ | 1 |
| Haynes, AP | 2 |
| Byrne, J | 1 |
| Cull, GM | 2 |
| Carter, GI | 2 |
| Pagliuca, A | 1 |
| Parker, JE | 1 |
| Mufti, G | 1 |
| Mahendra, P | 1 |
| Craddock, CF | 1 |
| Lui Yin, JA | 1 |
| Garg, M | 1 |
| Prentice, HG | 1 |
| Potter, MN | 1 |
| Russell, NH | 2 |
| Komrokji, RS | 1 |
| Oliva, JL | 1 |
| Zand, M | 1 |
| Felgar, R | 1 |
| Abboud, CN | 1 |
| Williams, KM | 1 |
| Higman, MA | 1 |
| Chen, AR | 1 |
| Schwartz, CL | 1 |
| Wharam, M | 1 |
| Colombani, P | 1 |
| Arceci, RJ | 1 |
| Byrne, JL | 1 |
| Miflin, G | 1 |
| Rebello, P | 1 |
| Hale, G | 1 |
| Waldmann, H | 1 |
| Altés, A | 1 |
| López, R | 1 |
| Martino, R | 1 |
| Martinez, C | 1 |
| Cabezudo, E | 1 |
| Muñoz, L | 1 |
| Santamaría, A | 1 |
| Perea, G | 1 |
| Briones, J | 1 |
| Salar, A | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Madoz, P | 1 |
| Sierra, J | 1 |
1 trial available for carmustine and Duncan Disease
| Article | Year |
|---|---|
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie | 2001 |
5 other studies available for carmustine and Duncan Disease
| Article | Year |
|---|---|
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoie | 2005 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2008 |
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; | 2000 |
Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Count; | 2000 |